rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-4-51-57rpcardio-686Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИMETOPROLOL AND CARVEDILOL IN THERAPY OF ACUTE MYOCARDIAL INFARCTION: WHEN AND WHICH DRUG TO PREFERМЕТОПРОЛОЛ И КАРВЕДИЛОЛ В ТЕРАПИИ ОСТРОГО ПЕРИОДА ИНФАРКТА МИОКАРДА: КОГДА И КАКОЙ ПРЕПАРАТ ПРЕДПОЧЕСТЬГарифуллинБ. Н.GarifullinB. N.

Башкортостан, 450000 Уфа, ул. Ленина, 3

Lenina ul. 3, Ufa, Bashkortostan, 450000

germes1981@list.ruЗакироваА. Н.ZakirovaA. N.

Башкортостан, 450000 Уфа, ул. Ленина, 3

Lenina ul. 3, Ufa, Bashkortostan, 450000

ЗарудийФ. С.ZarudijF. S.

Башкортостан, 450000 Уфа, ул. Ленина, 3

Lenina ul. 3, Ufa, Bashkortostan, 450000

Башкирский государственный медицинский университетРоссияBashkir State medical UniversityRussian Federation200910012016545157Copyright © Garifullin B.N., Zakirova A.N., Zarudij F.S., 20162016Гарифуллин Б.Н., Закирова А.Н., Зарудий Ф.С.Garifullin B.N., Zakirova A.N., Zarudij F.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/686

Results of large randomized clinical trails on beta-blockers therapy of myocardial infarction (MI) with ST segment elevation (COMMIT/CCS-2, CAPRICORN) are analyzed. Last changes in guidelines regarding beta-blockers prescription to patients with MI are presented. Data of the studies comparing influence of metoprolol tartrate and carvedilol on MI pathogenesis are presented. Possible indications and treatment schemes for carvedilol in patients with acute MI are discussed.

Анализируются результаты крупных рандомизированных контролируемых исследований бета-адреноблокаторов в терапии инфаркта миокарда (ИМ) c подъемом сегмента ST (COMMIT/CCS-2, CAPRICORN). Представлены последние изменения в рекомендациях относительно назначения бета-адреноблокаторов пациентам с ИМ. Обобщены данные исследований, сравнивавших влияние метопролола тартрата и карведилола на патогенез ИМ. Предложены возможные показания и схемы назначения карведилола в остром периоде ИМ.

инфаркт миокардабета-адреноблокаторкарведилолметопрололmyocardial infarctionbeta-blockercarvedilolmetoprololReferencesRandomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2(8498):57-66.Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2(8498):57-66.Chen Z.M., Pan H.C., Chen Y.P. et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1622-32.Chen Z.M., Pan H.C., Chen Y.P. et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1622-32.Menon V., Slater J.N., White H.D. et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000;108(5):374-80.Menon V., Slater J.N., White H.D. et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000;108(5):374-80.Metoprolol in acute myocardial infarction. Patient population. The MIAMI Trial Research Group. Am J Cardiol 1985;56(14):10G-14G.Metoprolol in acute myocardial infarction. Patient population. The MIAMI Trial Research Group. Am J Cardiol 1985;56(14):10G-14G.Karthikeyan G. Clopidogrel and metoprolol in myocardial infarction. Lancet 2006;367(9513):812.Karthikeyan G. Clopidogrel and metoprolol in myocardial infarction. Lancet 2006;367(9513):812.Borja J., García O., Donado E., Izquierdo I. Clopidogrel and metoprolol in myocardial infarction. Lancet 2006;367(9513):811-12.Borja J., García O., Donado E., Izquierdo I. Clopidogrel and metoprolol in myocardial infarction. Lancet 2006;367(9513):811-12.Swedberg K., Held P., Kjekshus J. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10):678–84.Swedberg K., Held P., Kjekshus J. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10):678–84.Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988;78(4):906–19.Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988;78(4):906–19.Терещенко С.Н., Жиров И.В. К вопросу о применении внутривенных β-адреноблокаторов у пациентов с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика 2007;(7):90-4.Терещенко С.Н., Жиров И.В. К вопросу о применении внутривенных β-адреноблокаторов у пациентов с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика 2007;(7):90-4.Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51(2):210-47.Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51(2):210-47.Antman E.M., Anbe D.T., Armstrong P.W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110(5):588-636.Antman E.M., Anbe D.T., Armstrong P.W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110(5):588-636.Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29(23):2909-45.Van de Werf F., Bax J., Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29(23):2909-45.Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385-90.Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357(9266):1385-90.Fonarow G.C., Lukas M.A., Robertson M. et al. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am Heart J 2007;154(4):637-44.Fonarow G.C., Lukas M.A., Robertson M. et al. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). Am Heart J 2007;154(4):637-44.Basu S., Senior R., Raval U. et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96(1):183-91.Basu S., Senior R., Raval U. et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96(1):183-91.Remme W.J., Torp-Pedersen C., Cleland J.G. et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007;49(9):963-71.Remme W.J., Torp-Pedersen C., Cleland J.G. et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007;49(9):963-71.Tölg R., Witt M., Schwarz B. et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention – the PASSAT Study. Clin Res Cardiol 2006;95(1):31-41.Tölg R., Witt M., Schwarz B. et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention – the PASSAT Study. Clin Res Cardiol 2006;95(1):31-41.Bonnemeier H., Ortak J., Tölg R. et al. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. Pacing Clin Electrophysiol 2005;28 Suppl 1:S217-21.Bonnemeier H., Ortak J., Tölg R. et al. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. Pacing Clin Electrophysiol 2005;28 Suppl 1:S217-21.Basat O., Ucak S., Seber S. et al. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol 2006;95(2):99-104.Basat O., Ucak S., Seber S. et al. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol 2006;95(2):99-104.Messerli F., Bell D., Fonseca V. et al. Body weight changes with beta-blockers use: results from GEMINI. Am J Med 2007;120(7):610-5.Messerli F., Bell D., Fonseca V. et al. Body weight changes with beta-blockers use: results from GEMINI. Am J Med 2007;120(7):610-5.Kastratović D.A., Vasiljević Z.M., Spasić M.B. et al. Carvedilol increases copperzinc superoxide dismutase activity in patients with acute myocardial infarction. Basic Clin Pharmacol Toxicol 2007;101(2):138-42.Kastratović D.A., Vasiljević Z.M., Spasić M.B. et al. Carvedilol increases copperzinc superoxide dismutase activity in patients with acute myocardial infarction. Basic Clin Pharmacol Toxicol 2007;101(2):138-42.β-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982; 247(12):1707-14.β-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA 1982; 247(12):1707-14.Norwegian Multicentre Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304(14):801-7.Norwegian Multicentre Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304(14):801-7.Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet 1981;2(8251):823-7.Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomized trial. Lancet 1981;2(8251):823-7.Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987;8(10):1056-64.Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987;8(10):1056-64.Sackner-Bernstein J.D. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Rev Cardiovasc Med 2003;4 Sup￾pl 3:S25-9.Sackner-Bernstein J.D. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Rev Cardiovasc Med 2003;4 Sup￾pl 3:S25-9.Herlitz J., Hjalmarson A., Swedberg K., et al. The influence of early intervention in acute myocardial infarction on long-term mortality and morbidity as assessed in the Göteborg metoprolol trial. Int J Cardiol 1986;10(3):291-301.Herlitz J., Hjalmarson A., Swedberg K., et al. The influence of early intervention in acute myocardial infarction on long-term mortality and morbidity as assessed in the Göteborg metoprolol trial. Int J Cardiol 1986;10(3):291-301.Herlitz J., Hjalmarson A., Swedberg K., et al. Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction. Acta Med Scand 1988;223(3):227-31.Herlitz J., Hjalmarson A., Swedberg K., et al. Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction. Acta Med Scand 1988;223(3):227-31.Freemantle N., Cleland J., Young P. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318(7200):1730-7.Freemantle N., Cleland J., Young P. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318(7200):1730-7.Center for Drug Evaluation and Research, U.S Food and Drug Administration. Statistical review and evaluation (amendment of clinical/statistical review of 12/04/02). Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3920B2_02_C-FDA-Coreg-Errata.pdfCenter for Drug Evaluation and Research, U.S Food and Drug Administration. Statistical review and evaluation (amendment of clinical/statistical review of 12/04/02). Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3920B2_02_C-FDA-Coreg-Errata.pdfCenter for Drug Evaluation and Research, U.S Food and Drug Administration. Transcript of the 98th meeting of the Cardiovascular and Renal Advisory Committee, January 7, 2003. Available at: www.fda.gov/ohrms/dockets/ac/03/transcripts/3920T2.htmCenter for Drug Evaluation and Research, U.S Food and Drug Administration. Transcript of the 98th meeting of the Cardiovascular and Renal Advisory Committee, January 7, 2003. Available at: www.fda.gov/ohrms/dockets/ac/03/transcripts/3920T2.htm

The authors declare that there are no conflicts of interest present.